Clinical outcomes of recommended active pharmacotherapy agents from NICE guideline for post-traumatic stress disorder: Network meta-analysis

Zhi-Xin Zhang,Run-Ben Liu,Jin Zhang,Chen-Yang Xian-Yu,Jia-Ling Liu,Xiao-Zheng Li,Yu-Qiang Zhang,Chao Zhang
DOI: https://doi.org/10.1016/j.pnpbp.2023.110754
IF: 5.201
2023-03-19
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Abstract:Background Post-traumatic stress disorder (PTSD) is a mental disorder that can emerge after an individual experiences a traumatic event such as physical abuse, sexual/relationship violence, combat exposure, witnessing death, or serious injury. This study aimed to identify the most suitable drugs for the management of PTSD based on a network meta-analysis (NMA). Methods Six databases (Ovid Medline, EMBase, CENTRAL, PsycINFO, Ovid Health and Psychosocial Instruments, and Web of Science) were searched from inception to September 6, 2022. Results Thirty articles with a total of 5170 participants were included. Compared with placebo, active drugs including olanzapine (SMD = −0.66, 95% CI: −1.19 to −0.13), risperidone (SMD = −0.23, 95% CI: −0.42 to −0.03), quetiapine (SMD = −0.49, 95% CI: −0.93 to −0.04), venlafaxine (SMD = −0.29, 95% CI: −0.42 to −0.16), sertraline (SMD = −0.23, 95% CI: −0.34 to −0.11), paroxetine (SMD = −0.48, 95% CI: −0.60 to −0.36) and fluoxetine (SMD = −0.27, 95% CI: −0.42 to −0.12), significantly reduced the total clinician-administered PTSD scale score. Conclusion The results of this study support the use of paroxetine, venlafaxine, and quetiapine as first-line treatment for PTSD. In addition, quetiapine is recommended for patients with PTSD affected by symptoms of hyperarousal and re-experience disorder. Clinicians should prescribe medications based on the severity of PTSD symptoms and other conditions to develop the best treatment strategy for this patient population.
pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology
What problem does this paper attempt to address?